One minute review of July events in the pharmaceutical industry

Just ended in July, the pharmaceutical industry was busy: nine ministries and commissions jointly issued the key points of 2016 special governance work to correct the unhealthy trend in pharmaceutical purchase and sale and medical services, which increased supervision and crackdown on four aspects of affiliation, false invoice, bill management and commercial bribery; the development and Reform Commission issued the division plan of key work departments of the guidance on promoting the healthy development of the pharmaceutical industry, Clearly put forward to improve the enterprise logistics information system and encourage the outflow of prescriptions; the General Administration publicly solicited the opinions of the measures for the administration of drug registration (Revised Version); the regulations for the administration of drug trade quality was revised; the list of inspection institutions responsible for the review of the first batch of 289 generic drugs for the conformity assessment of quality and efficacy was published Hebei Province issued the guiding opinions on further deepening the comprehensive reform of public hospitals, promoting the "two ticket system" from production enterprises to circulation enterprises, circulation enterprises to medical institutions, and the system of president responsibility for purchasing pharmaceutical consumables; Beijing, Tianjin and Hebei signed the "joint purchasing agreement for pharmaceutical medical consumables in Beijing, Tianjin and Hebei", and unified drug bidding and consumables purchasing; listed in Inner Mongolia The first batch of 50 key management catalog of auxiliary drugs has pushed the schedule of strict monitoring and management of auxiliary drugs forward a big step Fosun Pharmaceutical purchased India pharmaceutical company gland Pharma with 8.4 billion yuan Limited entered the international market, aimed at India's generic drug policy and expanded its R & D business scale; GSK innovative vaccine for cervical cancer prevention was approved to be listed in China; three pharmaceutical companies were fined more than 2.6 million yuan for reaching the monopoly agreement of eszolam bulk drug and tablet; who was the wrong person in the investigation of Hainan progesterone event was made hot; SCI was sold; licensed pharmacists in various provinces and cities registered hot, on-site trial There are a lot of strange moves in nuclear security measures What are the major policies and regulations issued by the pharmaceutical industry that can affect the industry? What are the major events that people are interested in or gaping at? What are the secrets and business opportunities behind the major events? Take a look at the following table: 1 Summary data source of policies and regulations of the pharmaceutical industry in July 2016: Pharmaceutical intelligence data 2 Summary of major events in the pharmaceutical industry in July 2016 note: for details of major events, please refer to the historical push article of this month in pharmaceutical intelligence news.